leadf
logo-loader
viewNovaBay Pharmaceuticals

NovaBay secures US$3mln bridge loan to commercialise eye product

Eye-care focused NovaBay Pharmaceuticals has secured a three year US$3 million bridge loan, it told investors.

woman-face.jpg
The eyes have it - NovaBay backers are providing a bridge loan

Eye-care focused NovaBay Pharmaceuticals (NYSE: NBY)has secured a three year US$3 million bridge loan, it told investors.

The group is focused on commercialising prescription Avenova lid and lash cleanser for the eye care market, which is formulated with Neutrox, which is cleared by the US Food and Drug Administration (FDA) as a medical device.

The loan, managed by China Kington Asset Management, is funded by five investors including NovaBay’s chairman and interim chief executive Mark Sieczkarek, NovaBay board members Gail Maderis and Dr Alex McPherson, as well as China Pioneer Pharma -  NovaBay’s largest shareholder.

The company has already received around US$1.66 million, with the remaining $1.37 million to be funded later this month.

“This loan provides NovaBay and our shareholders with non-dilutive funds as we focus on growing Avenova sales and achieving our target of positive cash flow from operations by the end of 2016,” said Sieczkarek.

“My decision to participate in the loan reflects my optimism with NovaBay’s new business model, and I’m delighted that China Kington and China Pioneer Pharma are demonstrating their ongoing confidence in NovaBay,” stated Ms. Maderis.

“With new record high sales every quarter since launched last year, we are encouraged by the early market traction for Avenova, and we are enthusiastic about the future prospects for NovaBay,” said Eric Wu, of China Kington Asset Management.

Quick facts: NovaBay Pharmaceuticals

Price: 0.73 USD

NYSEMKT:NBY
Market: NYSEMKT
Market Cap: $30.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE gets an injection of optimism from US Remdesivir approval

FTSE 100 got a lift as a first treatment for COVID-19, remdesivir, was approved in the US. London’s leading index added 41 points to 5,826 in early dealings. Gilead Inc (NASDAQ:GILD) produces remdesivir and it is said to cut COVID-19 recovery times by five days. According to the World Health...

12 minutes ago

2 min read